ADAG Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 mai 2024 @ 22:00):

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers...

Stats
Dagens volum	12 314.00
Gjennomsnittsvolum	34 280.00
Markedsverdi	123.53M
EPS	$0 ( 2024-04-02 )
Neste inntjeningsdato	( $-0.420 ) 2024-08-28
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.36
ATR14	$0.0550 (1.96%)

Adagene Inc. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner
OZEM	-1
BWIN	-0.833

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Adagene Inc. Økonomi

Annual	2023
Omsetning:	$18.11M
Bruttogevinst:	$18.11M (100.00 %)
EPS:	$-0.430

FY	2023
Omsetning:	$18.11M
Bruttogevinst:	$18.11M (100.00 %)
EPS:	$-0.430

FY	2022
Omsetning:	$9.29M
Bruttogevinst:	$9.29M (100.00 %)
EPS:	$-1.850

FY	2021
Omsetning:	$10.18M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.825

Financial Reports:

No articles found.

Adagene Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Adagene Inc.

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company\'s product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin\'s lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.